Bioporto A/s · OMXCOP:BIOPOR
Bioporto A/s — Investor Presentation (May 2023)
13 slides from Bioporto A/s's investor presentation, May 31, 2023
Slide 1: Empowering Early Detection of Kidney Injury
Empowering Early Detection of Kidney Injury Rights Offering May 31, 2023 © Copyright BioPorto
Slide 2: Forward-Looking Statements
Forward-Looking Statements References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company” or “BioPorto”), and any further information that may be made available in connection with the subject matte
Slide 3: Today's Agenda
Today’s Agenda • Significant Clinical Impact of Acute Kidney Injury (AKI) • FDA Submission Update • Participating in the Rights Offering • How to Exchange Rights into Shares • Timeline • Q&A © Copyright BioPorto | 3
Slide 4: Acute Kidney Injury (AKI) leads to poor outcomes if untreated
Acute Kidney Injury (AKI) leads to poor outcomes if untreated An abrupt loss of kidney function that develops rapidly over a few hours or days Progression of AKI Reduced Normal Increased Risk Damage Kidney Kidney Failure Death Function • Cardiac Surgery • Mechanical Ventilation • Transplant • Sepsis
Slide 5: AKI - an unmet clinical need for early diagnosis
AKI - an unmet clinical need for early diagnosis AKI is Common & Costly Serum Creatinine Value of Early Identification eAlert + biomarkers7 • 1 in 5 adults1 and • 2-3 days delayed response • higher rate of AKI recovery 1 in 4 children2 (+22%) • 13.3 million per year • confounded by age, muscle mass,
Slide 6: US Market: Initial FDA Authorization for Pediatric Patients
US Market: Initial FDA Authorization for Pediatric Patients We will establish a beachhead in the US market focused on testing pediatric patients • Currently, 30+ US hospitals utilize the RUO NGAL test clinically as a Lab Developed Test (LDT) • Achieved Breakthrough Status with the FDA due to the sig
Slide 7: Rights offering of DKK 59.4M with Pre-Emptive Rights
Rights offering of DKK 59.4M with Pre-Emptive Rights DKK 16.6M (28%) is Already Subscribed • Major shareholders • Entire Board of Directors • Management team members Builds upon Cost Control and Working Capital Management Activities All Shareholders Can Participate on the Same Terms © Copyright BioP
Slide 8: Rights offering of DKK 59.4M with Pre-Emptive Rights
Rights offering of DKK 59.4M with Pre-Emptive Rights DKK 16.6M (28%) is Already Subscribed Proceeds Strengthen Capital Resources • Major shareholders • Advance implementation of strategic • Entire Board of Directors priorities: • Management team members o Grow revenues in European and other markets
Slide 9: How to Participate in the Offering at DKK 1.00/share
How to Participate in the Offering at DKK 1.00/share 1. Exercise Rights • Shareholders: contact your bank to exercise your pre-emptive rights • Anyone: buy rights on the market & exercise them through your bank (ISIN DK0062496477) 2. Subscribe for any Remaining Shares(a) • Anyone(b): contact BioPort
Slide 10: Targeted rights offering of DKK 59.4M: exchange ratio 3:17
Targeted rights offering of DKK 59.4M The exchange ratio is 3:17 Each holder of existing Will be allocated 17 Pre-Emptive Rights shares in BioPorto 3 Pre-Emptive Rights + DKK 1.00 Subscription registered as such with for each Existing Share Price Euronext Securities held = 1 New Share on May 31st ©
Slide 11: Example pre-emptive rights issue
Targeted rights offering of DKK 59.4M The exchange ratio is 3:17 Each holder of existing Will be allocated 17 Pre-Emptive Rights shares in BioPorto 3 Pre-Emptive Rights + DKK 1.00 Subscription registered as such with for each Existing Share Price Euronext Securities held = 1 New Share on May 31st Ex
Slide 12: Key Dates
KEY DATES Subscription Period • First day: 6 June 2023 • Last day: 19 June 2023 Rights Trading Period • First day: 1 June 2023 Payment for New Shares must be made in DKK on the date of • Last day: 15 June 2023 subscription and in no event later than June 19, 2023 at 17:00 CEST. © Copyright BioPorto
Slide 13: Thank you
Thank you CPH: BIOPOR Contact: Tim Ericksen Zenith Advisory investor@bioporto.com © Copyright BioPorto